Sign In
Buy CYTK
$77.13
-3.29 (-4.09%)
At Close: Jul 31, 2026
Cytokinetics wins UK approval, NICE backing for heart disease drug
06:48am, Thursday, 30'th Jul 2026
Britain's medicines regulator approved Cytokinetics' drug for a rare heart condition on Thursday, with the country's cost-effectiveness watchdog recommending it for NHS reimbursement, potentially r
Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) --
Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise
01:39pm, Wednesday, 22'nd Jul 2026
Cytokinetics (CYTK) is positioned to expand MYQORZO across the entire HCM continuum, not just as a late-stage competitor to Camzyos. Initial MYQORZO launch metrics—rapid market access, >30% new-to-b
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 17'th Jul 2026
SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 15, 2026 it granted stock options to purchase an aggregate of 21,2
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy
01:01pm, Wednesday, 15'th Jul 2026
Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet
10:55am, Wednesday, 15'th Jul 2026
The mean of analysts' price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ana
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%
05:20pm, Tuesday, 14'th Jul 2026
The insider liquidated 7,500 shares at a weighted average price of $82.02. The disposition represented 2% of the executive's total reported equity holdings.
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
03:11pm, Friday, 10'th Jul 2026
CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best?
07:40am, Tuesday, 07'th Jul 2026
IWN delivered a 37.4% one-year return but carries higher fees, while ISCV offers a 0.06% expense ratio and stronger dividend yield of 1.9%.
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
07:30am, Tuesday, 07'th Jul 2026
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
Entertainment Stocks Madison Square Garden, Sphere Rally To New Highs
02:40pm, Friday, 26'th Jun 2026
Entertainment leader Sphere stock continues to outperform in the current market environment, setting new highs.
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
08:15am, Thursday, 25'th Jun 2026
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical asse
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Wednesday, 17'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,7
Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?
11:56am, Wednesday, 17'th Jun 2026
CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
03:58am, Tuesday, 09'th Jun 2026
Cytokinetics, Incorporated (CYTK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
